Vernon Bernardino

Novavax, Inc. (NASDAQ: NVAX) shares were roaring higher Friday after the company reported topline results from the late-stage trial of its coronavirus vaccine candidate in the U.K. The Novavax Analyst: H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating and $207 price target for...

Novavax, Inc. (NASDAQ: NVAX) announced late Thursday the initiation of a late-stage study of its investigational coronavirus vaccine, NVX-CoV2373, in the U.K. The Novavax Analysts: H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax with a $290 price target...

Novavax, Inc. (NASDAQ: NVAX) released better-than-expected bottom-line results for the second quarter Monday, although revenue trailed estimates. An analyst at H.C. Wainwright said they're focusing on the key milestone events for the company's coronavirus vaccine candidate after the...

Novavax, Inc. (NASDAQ: NVAX) shares are on a dream run this year amid catalysts including its COVID-19 vaccine program. The Novavax Analyst: Vernon Bernardino reiterated a top pick Buy rating on Novavax and raised the price target from $50 to $101.  The Novavax Thesis: Novavax...

Novavax, Inc. (NASDAQ: NVAX) announced Monday after the close an award of an incremental $384 million in funding by the Coalition for Epidemic Preparedness Innovations alongside forecast-beating first-quarter results. The Novavax Analysts H.C. Wainwright analyst Vernon Bernardino reiterated a Buy...

The thinly traded micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) is on investors' radars ahead of a Sept. 18 poster presentation of clinical data. The company is set to present at the European Association for the Study of Diabetes 55th annual meeting with results from the Part...

Abeona Therapeutics Inc (NASDAQ: ABEO), which employs gene and cell therapy for potential rare disease treatments, has a favorable risk-reward profile, according to Seaport Global Securities. The Analyst Analyst Vernon Bernardino initiated coverage of Abeona Therapeutics with a...